Karim Kasmi

Karim Kasmi

Company: Boehringer Ingelheim

Job title: Senior Principal Scientist

Seminars:

Closing Panel: The Future of Innate Immune Checkpoints & Activation 2:30 pm

Delving into the horizons of homing of innate cells and reprograming of the tumor microenvironment Discussing novel checkpoint inhibitors Analysing the various immunotherapy approaches discussed & beyond Updates on clinical trials for immunotherapies In vitro models and discovery technologies for innate cell-based therapies New methodologies of analyzing innate immune cells in the tumor microenvironment (scRNAseq,…Read more

day: Innate Immune Checkpoints & Activation Pre-Focus Day

The Anti-Fibrotic Drug Nintedanib Promotes Resolution Phenotype Macrophages 1:30 pm

Read more

day: Innate Immune Checkpoints & Activation Pre-Focus Day

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.